For patients with chronic and small lymphocytic leukemia, statin use is associated with improved survival, regardless of treatment employed.

Age and social jetlag demonstrate a significant negative association, suggesting a balancing of social and biological clocks upon retirement.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial.

Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD).

An intensive BP reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and older with untreated hypertension.

Implantable cardioverter-defibrillator therapy in patients with Brugada syndrome is effective for prevention of fatal arrhythmias.

A scientific statement regarding risk-based primary prevention of heart failure has been published by the American Heart Association.

The FDA has extended the review period for the NDA for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy.

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

The Food and Drug Administration (FDA) has cleared the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD).

Maternal mortality rates in the US remain high, especially compared with those of similarly wealthy countries, despite ...